Clinical Trial Update: Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating panitumumab with irinotecan as third-line therapy for metastatic colorectal cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Irinotecan (Irinotecan)
• Panitumumab (panitumumab)

Snippet

Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-09-21